JP2005516605A - 心血管疾患を処置するための方法および組成物 - Google Patents

心血管疾患を処置するための方法および組成物 Download PDF

Info

Publication number
JP2005516605A
JP2005516605A JP2003565410A JP2003565410A JP2005516605A JP 2005516605 A JP2005516605 A JP 2005516605A JP 2003565410 A JP2003565410 A JP 2003565410A JP 2003565410 A JP2003565410 A JP 2003565410A JP 2005516605 A JP2005516605 A JP 2005516605A
Authority
JP
Japan
Prior art keywords
regulator
polypeptide
nucleic acid
endogenous
nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003565410A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005516605A5 (https=
Inventor
トーマス ジョセフ ローガン，
ミヤング チュン，
キャサリン エム． ガルビン，
アイリーン ヒーリー，
スーザン エル． アクトン，
マリー ドナギュー，
ナンシー スタグリアノ，
ジャクリーン ペロディン，
アメリー ロドリギュー−ウェイ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2005516605A publication Critical patent/JP2005516605A/ja
Publication of JP2005516605A5 publication Critical patent/JP2005516605A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
JP2003565410A 2002-02-01 2003-01-29 心血管疾患を処置するための方法および組成物 Pending JP2005516605A (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US35322402P 2002-02-01 2002-02-01
US36452902P 2002-03-15 2002-03-15
US37386102P 2002-04-19 2002-04-19
US37628702P 2002-04-29 2002-04-29
US38808002P 2002-06-12 2002-06-12
US39097102P 2002-06-24 2002-06-24
US39413002P 2002-07-03 2002-07-03
US39479702P 2002-07-10 2002-07-10
US40490402P 2002-08-21 2002-08-21
US40545002P 2002-08-23 2002-08-23
US40807002P 2002-09-04 2002-09-04
US42430002P 2002-11-06 2002-11-06
US43107902P 2002-12-05 2002-12-05
US43104202P 2002-12-05 2002-12-05
PCT/US2003/002571 WO2003065984A2 (en) 2002-02-01 2003-01-29 Methods and compositions for treating cardiovascular disease

Publications (2)

Publication Number Publication Date
JP2005516605A true JP2005516605A (ja) 2005-06-09
JP2005516605A5 JP2005516605A5 (https=) 2006-03-16

Family

ID=27739580

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003565410A Pending JP2005516605A (ja) 2002-02-01 2003-01-29 心血管疾患を処置するための方法および組成物

Country Status (5)

Country Link
US (1) US20030215840A1 (https=)
EP (1) EP1470240A4 (https=)
JP (1) JP2005516605A (https=)
AU (1) AU2003212850A1 (https=)
WO (1) WO2003065984A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500875A (ja) * 2006-08-21 2010-01-14 アイトゲネシシェ・テヒニーシェ・ホッホシューレ・チューリッヒ Ｆｙｎキナーゼの改変ｓｈ３ドメインを含む特異的かつ高親和性の結合タンパク質
US9513296B2 (en) 2006-08-21 2016-12-06 Eidgenoessische Technische Hochschule Zurich Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase
US9689879B2 (en) 2006-08-21 2017-06-27 Eidgenoessische Technische Hochschule Zurich Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003050504A2 (en) * 2001-12-10 2003-06-19 Millennium Pharmaceuticals, Inc. Methods and compositions to treat cardiovascular disease usin g 1419, 58765 and 2201
CN100473662C (zh) 2002-08-01 2009-04-01 阿瑞那制药公司 治疗缺血性心脏病及充血性心衰竭的人类g蛋白偶联受体及其调节物
DE10240385B4 (de) * 2002-08-31 2004-08-26 Ruprecht-Karls-Universität Heidelberg Verfahren zur Diagnose einer Dünndarmzottengewebeatrophie
US20080260744A1 (en) 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
US20050037946A1 (en) * 2003-01-13 2005-02-17 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 41922, 2552, 2417, 19319, 43969, 8921, 8993, 955, 32345, 966, 1920, 17318, 1510, 14180, 26005, 554, 16408, 42028, 112091, 13886, 13942, 1673, 54946 or 2419
WO2005103290A1 (en) * 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with aspartyl aminopeptidase (dnpep)
CA2604333A1 (en) * 2005-04-15 2006-10-19 Cenix Bioscience Gmbh Human marker genes and agents for cardiovascular disorders and artherosclerosis
EP2035574A1 (en) * 2006-06-17 2009-03-18 Bayer HealthCare AG Use of n-acylaminoacylpeptide hydrolase (apeh) as a therapeutic or diagnostic target
WO2008046543A1 (en) * 2006-10-16 2008-04-24 Bayer Healthcare Ag Cell protective genes
EP2091556B1 (en) * 2006-11-15 2018-07-25 Omeros Corporation Non-human animal comprising a mutation in the sreb2/gpr85 gene as animal model of metabolic disease
CN102325449A (zh) * 2008-12-19 2012-01-18 安塞拉制药有限公司 用分泌磷脂酶A2(sPLA2)抑制剂或sPLA2抑制剂组合疗法处理主要不良心血管事件和急性冠状动脉综合症的方法
EP2305717A1 (en) * 2009-09-21 2011-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Inhibiting TNIK for treating colon cancer
KR102271498B1 (ko) 2013-08-30 2021-07-05 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 종양 치료를 위한 키누레닌 고갈 효소의 투여
EP3423483B1 (en) 2016-03-02 2025-09-24 Board Of Regents Of the University Of Texas System Human kynureninase enzyme variants having improved pharmacological properties
BR112020020772A2 (pt) 2018-04-16 2021-02-02 Board Of Regents, The University Of Texas System enzimas quinureninase humana e usos das mesmas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321120A (en) * 1980-03-19 1982-03-23 Nardi Ronald V Process for detecting proteins specific to hypertension in mammals
FR2780512B1 (fr) * 1998-06-25 2003-10-17 Lipha Utilisation de recepteurs de la famille rev-erb pour le criblage de substances utiles dans le traitement des dysfonctionnements du metabolisme lipidique
CA2256123A1 (en) * 1998-12-31 2000-06-30 Centre De Recherche Du Centre Hospitalier De L'universite De Montreal A novel hypertension related calcium regulated gene (hcarg)
US6764826B2 (en) * 2000-06-08 2004-07-20 Board Of Regents, The University Of Texas System Inhibitors of C-reactive protein induced inflammation
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500875A (ja) * 2006-08-21 2010-01-14 アイトゲネシシェ・テヒニーシェ・ホッホシューレ・チューリッヒ Ｆｙｎキナーゼの改変ｓｈ３ドメインを含む特異的かつ高親和性の結合タンパク質
JP2013078316A (ja) * 2006-08-21 2013-05-02 Eidgenoessische Technische Hochschule Zuerich Ｆｙｎキナーゼの改変ｓｈ３ドメインを含む特異的かつ高親和性の結合タンパク質
US9513296B2 (en) 2006-08-21 2016-12-06 Eidgenoessische Technische Hochschule Zurich Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase
US9689879B2 (en) 2006-08-21 2017-06-27 Eidgenoessische Technische Hochschule Zurich Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase
US9989536B2 (en) 2006-08-21 2018-06-05 Eidgenoessische Technische Hochschule Zurich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
US10996226B2 (en) 2006-08-21 2021-05-04 Eidgenoessische Technische Hochschule Zurich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase

Also Published As

Publication number Publication date
AU2003212850A1 (en) 2003-09-02
WO2003065984A3 (en) 2004-03-18
US20030215840A1 (en) 2003-11-20
WO2003065984A2 (en) 2003-08-14
EP1470240A4 (en) 2006-08-30
EP1470240A2 (en) 2004-10-27
AU2003212850A8 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
JP2005516605A (ja) 心血管疾患を処置するための方法および組成物
JP2007520996A (ja) ４４３９０、５４１８１、２１１、５６８７、８８４、１４０５、６３６、４４２１、５４１０、３０９０５、２０４５、１６４０５、１８５６０、２０４７、３３７５１、５２８７２、１４０６３、２０７３９、３２５４４、４３２３９、４４３７３、５１１６４、５３０１０、１６８５２、１５８７、２２０７、２２２４５、２３８７、５２９０８、６９１１２、１４９９０、１８５４７、１１５、５７９、１５９８５、１５６２５、７６０、１８６０３、２３９５、２５５４、８６７５、３２７２０、４８０９、１４３０３、１６８１６、１７８２７、３２６２０、５７７、６１９、１４２３、２１５８、８２６３、１５４０２、１６２０９、１６３８６、２１１６５、３０９１１、４１８９７、１６４３、２５４３、９６２６、１３２３１、３２４０９、８４２６０、２８８２、８２０３、３２６７８または５５０５３を用いて泌尿器科障害を処置するための方法および組成物
US20050037946A1 (en) Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 41922, 2552, 2417, 19319, 43969, 8921, 8993, 955, 32345, 966, 1920, 17318, 1510, 14180, 26005, 554, 16408, 42028, 112091, 13886, 13942, 1673, 54946 or 2419
US20040091929A1 (en) Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941
US20050142604A1 (en) Methods and compositions to treat cardiovascular disease using 1419, 58765 and 2210
JP2005525112A (ja) ジアシルグリセロールキナーゼεを使用して疼痛を処置する際の方法および組成物
WO2002012887A2 (en) Methods and compositions for the diagnosis and treatment of brown adipose cell disorders
US20060088881A1 (en) Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 molecules
JP2005507673A (ja) １３９、２５８、１２６１、１４８６、２３９８、２４１４、７６６０、８５８７、１０１８３、１０５５０、１２６８０、１７９２１、３２２４８、６０４８９または９３８０４を用いる心血管疾患を治療するための方法および組成物
US20020151480A1 (en) Methods and compositions for treating cardiovascular disease using 10218
JP2006519983A (ja) １６３８６、１５４０２、２１１６５、１４２３、６３６、１２３０３、２１４２５、２７４１０、３８５５４、３８５５５、５５０６３、５７１４５、５９９１４、９４９２１、１６８５２、３３２６０、５８５７３、３０９１１、８５９１３、１４３０３、１６８１６、１７８２７、または３２６２０を使用する、疼痛および疼痛障害を処置する方法および組成物
US20040077001A1 (en) Use for carboxypeptidase-A4 in the diagnosis and treatment of metabolic disorders
WO2003053364A2 (en) Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908
US20030152970A1 (en) Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
JP2005507665A (ja) ４６５６６を用いた疼痛障害の処置および診断のための方法および組成物
US20070179102A1 (en) Methods and compositions for the treatment and diagnosis of pain disorders using 9805, 2047, 46566, 57749, 577, 20739, 57145, 1465, 1587, 2146, 2207, 32838, 336 or 52908
WO2001064872A2 (en) Gene 2465: methods and compositions for the diagnosis and treatment of cardiovascular, hepatic and bone disease
US20030104455A1 (en) Methods and compositions for treating urological disorders using 313, 333, 5464, 18817 or 33524
JP2005508173A (ja) ２３２、２０５９、１０６３０、１２８４８、１３８７５、１４３９５、１４６１８、１７６９２または５８８７４を使用する血液障害を処置するための方法および組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060713

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20060713

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20060713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090519